Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (84)	10/11/2000 1:33:44 PM
From: tuck	Respond to of 255

>>Eleazar Shafrir, a professor of biochemistry at Hadassah University Hospital in Jerusalem, who was not connected with the research, said he doubted inhaled insulin could entirely replace injections. "It's not going to be effective for long-range treatment of patients," Shafrir said, adding that an alternative to injections would be most useful for children who are likely to develop Type I diabetes.<< Dr. Shafrir sounds pretty sure of himself. I wonder if he has any industry associations. How does he know inhaled insulin won't be an effective long-range treatment? Is there some known pulmonary limit, a time at which some sort adverse reaction to this form of delivery develops? The article can't be accused of hyping the technology, that's for sure. If anything slanted a bit in the other direction. Whose unreferenced study was that, anyway? Cheers, Tuck